Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

The Number of Signaling Pathways Altered by Driver Mutations in Chronic Lymphocytic Leukemia Impacts Disease Outcome

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. A Phase II Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Comparative Assessment of Diagnostic Homologous Recombination Deficiency-Associated Mutational Signatures in Ovarian Cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Clinical Outcomes in Patients with Multi-Hit TP53 Chronic Lymphocytic Leukemia Treated with Ibrutinib

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Detection of Molecular Signatures of Homologous Recombination Deficiency in Bladder Cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Identifying patients with chronic lymphocytic leukemia without need of treatment: End of endless watch and wait?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. The CLL comorbidity index in a population-based cohort: a tool for clinical care and research

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Impact of specific high-risk human papillomavirus genotypes on survival in oropharyngeal cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Severity and 90-day survival of SARS-CoV-2 infection among patients with haematological disorders

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

Vis graf over relationer

PURPOSE: Investigation of signaling pathways altered by recurrent gene mutations and their clinical impact in a consecutive cohort of patients with newly diagnosed chronic lymphocytic leukemia (CLL). The heterogeneous clinical course and genetic complexity of CLL warrant improved molecular prognostication. However, the prognostic value of recurrent mutations at time of diagnosis remains unclear.

EXPERIMENTAL DESIGN: We sequenced samples from 314 consecutive, newly diagnosed patients with CLL to investigate the clinical impact of 56 recurrently mutated genes assessed by next-generation sequencing.

RESULTS: Mutations were identified in 70% of patients with enrichment among IGHV unmutated cases. With 6.5 years of follow-up, 15 mutated genes investigated at time of diagnosis demonstrated significant impact on time to first treatment (TTFT). Carrying driver mutations was associated with shorter TTFT and poor overall survival. For outcome from CLL diagnosis, the number of signaling pathways altered by driver mutations stratified patients better than the number of driver mutations. Moreover, we demonstrated gradual impact on TTFT with increasing number of altered pathways independent of CLL-IPI risk. Thus, a 25-gene, pathway-based biomarker assessing recurrent mutations refine prognostication in CLL; in particular for CLL-IPI low and intermediate risk patients. External validation emphasized that a broad gene panel including low burden mutations was key for the biomarker based on altered pathways.

CONCLUSIONS: We propose to include the number of pathways altered by driver mutations as a biomarker together with CLL-IPI in prospective studies of CLL from time of diagnosis for incorporation into clinical care and personalized follow-up and treatment.

OriginalsprogEngelsk
TidsskriftClinical Cancer Research
Vol/bind26
Udgave nummer6
Sider (fra-til)1507-1515
Antal sider9
ISSN1078-0432
DOI
StatusUdgivet - 15 mar. 2020

Bibliografisk note

Copyright ©2020, American Association for Cancer Research.

ID: 59005280